ClearPoint Neuro, Inc. · Healthcare · Medical Devices
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$9.53
+$0.29 (+3.14%) 12:00 PM ET
Prev closePrevC$9.24
OpenOpen$9.17
Day highHigh$9.54
Day lowLow$9.09
VolumeVol239,251
Avg volAvgVol718,887
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$281.86M
EV/Sales
7.16
P/E ratio
-8.43
FY Revenue
$42.28M
EPS
-1.13
Gross Margin
62.61%
Div yield
0.00%
Sector
Healthcare
AI report sections
MIXED
CLPT
ClearPoint Neuro, Inc.
No AI report section text found yet for this symbol.
AI summarized at 9:01 AM ET, 2026-09-29
AI summary scores
INTRADAY:38SWING:26LONG:24
Volume vs average
Intraday (cumulative)
+33% (Above avg)
Vol/Avg: 1.33×
RSI
27.67(Oversold)
Oversold (<30)
0255075100
MACD momentum
Intraday
+0.00 (Strong)
MACD: 0.01 Signal: 0.01
Short-Term
-0.27 (Weak)
MACD: -1.22 Signal: -0.95
Long-Term
-0.34 (Weak)
MACD: -1.40 Signal: -1.05
Intraday trend score
39.02
LOW30.26HIGH44.97
Latest news
CLPT•12 articles•Positive: 0Neutral: 2Negative: 1
NegativeGlobeNewswire Inc.• Pomerantz Llp
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
Pomerantz LLP is investigating potential securities fraud claims against ClearPoint Neuro following a significant stock price decline. On September 29, 2026, development partner uniQure announced that their joint treatment for Huntington's disease failed to achieve statistical significance on a primary clinical measure at 48 months, causing ClearPoint's stock to plummet 23.12% to $11.77 per share.
Company experienced a significant 23.12% stock price decline following announcement that its development partner's clinical trial failed to meet primary endpoints. The investigation into potential securities fraud further compounds negative sentiment.
AngioDynamics reported a quarterly loss of $0.04 per share, beating consensus estimates of $0.10 loss by 60%, but missed revenue expectations with $80.92 million versus the estimated $81.85 million. The medical device company has a Zacks Rank #3 (Hold) rating with mixed estimate revisions. The Medical-Instruments industry ranks in the top 39% of Zacks industries.
Expected to report significant quarterly loss of $0.27 per share with 28.6% year-over-year deterioration, though revenues are expected to grow 41.1%. Consensus estimates unchanged over last 30 days, indicating stable but challenging outlook.
NeutralGlobeNewswire Inc.• Sabyasachi Ghosh
Global MRI Guided Neurosurgical Ablation Market Poised for Steady Growth, Projected to Reach USD 227.56 Million by 2034 Driven by Growing Adoption and Advancements in Non-Cooled Laser Systems: FMI
The global MRI-guided neurosurgical ablation market is expected to grow significantly, reaching a value of USD 227.56 million by 2034, driven by advancements in technology, regulatory approvals, and enhanced healthcare accessibility.
ClearPoint Neuro, Inc. is listed as one of the key players in the MRI-guided neurosurgical ablation industry, but the article does not provide any specific details about the company's recent developments or performance.
UnknownGlobeNewswire Inc.• ClearPoint Neuro, Inc.
ClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical Trial
ClearPoint® Navigation System to be used for all enrolled patients in Aspen's ASPIRO Parkinson's cell therapy clinical trial
CLPTPartnershipsClinical Study
UnknownZacks Investment Research• Zacks Equity Research
ClearPoint's (CLPT) New Products to Boost Neurosurgical Segment
ClearPoint (CLPT) announces the full market release of the SmartFrame OR platform, intended for performing DBS, and Prism Neuro Laser Therapy System for providing thermal therapy.
BSXECLALGNCLPT
UnknownGlobeNewswire Inc.• ClearPoint Neuro, Inc.
ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System
Newly Launched ClearPoint Neuro technology - SmartFrame OR and Prism Laser will be on display at ASSFN in Nashville from June 1 - 4
CLPTProduct / Services AnnouncementCalendar of Events
UnknownZacks Investment Research• Zacks Equity Research
Does ClearPoint Neuro (CLPT) Have the Potential to Rally 81.49% as Wall Street Analysts Expect?
The consensus price target hints at an 81.5% upside potential for ClearPoint Neuro (CLPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
CLPT
UnknownZacks Investment Research• Zacks Equity Research
Wall Street Analysts Predict a 70.65% Upside in ClearPoint Neuro (CLPT): Here's What You Should Know
The mean of analysts' price targets for ClearPoint Neuro (CLPT) points to a 70.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CLPT
UnknownZacks Investment Research• Zacks Equity Research
Rapid Micro Biosystems (RPID) delivered earnings and revenue surprises of -6.90% and 0.74%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
RPIDCLPT
UnknownZacks Investment Research• Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue Estimates
Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of 21.25% and 10.76%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
TNDMCLPT
UnknownGlobeNewswire Inc.• ClearPoint Neuro, Inc.
ClearPoint Neuro félicite son partenaire AviadoBio pour son premier patient traité dans le cadre de son essai clinique ASPIRE-FTD évaluant l’AVB-101 dans la démence fronto-temporale avec mutations du gène GRN
Les centres ASPIRE-FTD dans l’UE et aux États-Unis utiliseront la navigation ClearPoint® avec la canule SmartFlow® pour l’administration de thérapie génique intrathalamique Les centres ASPIRE-FTD dans l’UE et aux États-Unis utiliseront la navigation ClearPoint® avec la canule SmartFlow® pour l’administration de thérapie génique intrathalamique
CLPTHealthClinical Study
UnknownGlobeNewswire Inc.• ClearPoint Neuro, Inc.
ClearPoint Neuro beglückwünscht seinem Partner AviadoBio zur Behandlung des ersten Patienten in der klinischen Studie ASPIRE-FTD, in der AVB-101 für frontotemporale Demenz mit GRN-Mutationen evaluiert wird
Prüfzentren für ASPIRE-FTD in der EU und den USA verwenden ClearPoint® Navigation zusammen mit der SmartFlow®-Kanüle für die intrathalamische Gentherapie Prüfzentren für ASPIRE-FTD in der EU und den USA verwenden ClearPoint® Navigation zusammen mit der SmartFlow®-Kanüle für die intrathalamische Gentherapie
CLPTHealthClinical Study
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
